APYX is executing a credible pivot to a recurring revenue, platform-driven model in a rapidly expanding body contouring market. The AON system’s integration of multiple technologies and new FDA-cleared features offers real differentiation, though defensibility will depend on sustained clinical vali…
APYX Q2 2026: Surgical Aesthetics Up 28% as AON Platform Drives Mix Shift
APYX delivered a fourth straight quarter of double-digit growth in surgical aesthetics, powered by AON adoption and expanded FDA clearances. The business is now squarely focused on capturing the post-GLP-1 body contouring opportunity, while OEM revenue and legacy segments recede. With power liposuction now shipping, management is betting on recurring handpiece sales and platform stickiness to accelerate operating leverage into 2027.
Summary
- AON Platform Penetration: New FDA-cleared features and growing surgeon adoption are shifting revenue mix toward higher-margin surgical aesthetics.
- Recurring Revenue Focus: Expanded handpiece portfolio and consumables strategy aim to drive repeat sales per account.
- Cash Burn and Margin Watch: Improving loss trajectory, but working capital and manufacturing scale-up remain key to reaching cash flow breakeven.
Business Overview
APYX Medical is a medical device company specializing in energy-based surgical solutions for the aesthetics market, with a growing focus on body contouring. The company generates revenue through sales of capital equipment platforms (notably AON and Renuvion), single-use and reusable handpieces, and consumables to plastic and cosmetic surgeons. Its business is divided into two primary segments: Surgical Aesthetics, its growth engine, and OEM, a legacy contract manufacturing business. The company’s core differentiation lies in integrated, multi-technology platforms that address both fat removal and tissue contraction for body contouring procedures.
Performance Analysis
APYX posted 22% total revenue growth, driven by a 28% increase in surgical aesthetics, which now accounts for nearly 90% of total sales. The AON body contouring system was the key growth driver, with expanding adoption among both existing and new surgeon customers. International sales of generators and rising domestic handpiece utilization also contributed to the top line.
Gross margin expanded to 63.9%, reflecting favorable mix shift toward surgical aesthetics and improved product mix within the OEM segment, despite ongoing tariff headwinds. Operating loss narrowed on higher gross profit, but operating expenses grew due to increased sales and marketing investment and headcount. Cash used in operations increased sequentially, reflecting working capital needs tied to the AON rollout and initial power liposuction shipments. The OEM segment declined 12% and is expected to further contract as the company prioritizes its proprietary platform strategy.
- Surgical Aesthetics Mix Shift: Segment now dominates revenue, improving gross margin profile and recurring revenue potential.
- OEM Decline Accelerates: Legacy contract manufacturing now a small and shrinking part of the portfolio.
- Margin Expansion Offset by Scale-Up Costs: Early-stage manufacturing of power lipo handpieces weighs on near-term gross margin, but management expects improvement as throughput increases.
Net loss and adjusted EBITDA improved year over year, but cash burn remains a watchpoint as APYX invests in commercial expansion and product launches.
Executive Commentary
"US surgeons are increasingly recognizing the value of our integrated all-in-one body contouring platform, which combines the core technologies they rely on every single day into a single streamlined system. We believe the growing adoption reinforces Aon's differentiated value proposition."
Charlie Goodwin, President and Chief Executive Officer
"We are focused on growing sales, managing expenses, and getting to cash flow positive as quickly as possible."
Matt Hill, Chief Financial Officer
Strategic Positioning
1. AON Platform as Growth Engine
The full commercial launch of AON, an all-in-one body contouring system, is transforming APYX’s revenue base. The recent FDA clearance for power liposuction adds a critical feature, enabling APYX to address both fat removal and tissue tightening in a single platform. The company is targeting plastic and cosmetic surgeons, particularly those treating patients post-GLP-1 medication-induced weight loss.
2. Recurring Revenue and Consumables Model
With power lipo handpieces and consumables now in market, APYX is building a base of recurring procedure-driven revenue. Handpieces are reusable but have a finite lifespan, and each procedure uses additional consumables, creating ongoing sales per installed system. Management expects nearly all new AON systems to ship with power lipo capability, deepening account penetration.
3. Clinical Data and Surgeon Engagement
Peer-reviewed studies published this quarter demonstrated higher patient satisfaction and reduced revision rates when combining Renuvion with liposuction, supporting the clinical differentiation narrative. APYX is actively leveraging these findings to drive surgeon education and platform adoption, as evidenced by its presence at high-visibility events like Miami Swim Week.
4. OEM Wind-Down and Focused Capital Allocation
The legacy OEM segment continues to shrink, freeing resources and management attention for the core aesthetics business. Leadership is explicit that future growth and investment are concentrated on proprietary platforms and consumables, not contract manufacturing.
5. Operational Scale and Margin Leverage
Initial shipments of power lipo handpieces are expensive due to low volumes, but management expects unit costs to decline as manufacturing ramps. Margin expansion will depend on scaling throughput and optimizing supply chain as commercial adoption grows.
Key Considerations
This quarter marks a clear pivot toward platform-driven, recurring revenue in a market reshaped by new patient demographics and clinical needs. Management is betting on technology integration, clinical data, and a consumables model to deliver sustainable growth and margin improvement.
Key Considerations:
- GLP-1 Patient Trend: Rapid adoption of GLP-1 weight loss drugs is expanding the addressable market for body contouring procedures, creating a tailwind for AON adoption.
- Platform Stickiness: Integrated features and clinical outcomes are driving both new customer wins and deeper penetration with existing accounts.
- Recurring Revenue Ramp: Handpiece and consumable sales per procedure are critical for margin leverage and long-term account monetization.
- Cash Flow Path: Despite improved loss trajectory, working capital and manufacturing investments will test liquidity until scale is achieved.
- Tariff and Cost Pressures: Tariffs and early-stage manufacturing inefficiencies remain headwinds, though management expects improvement as volumes grow.
Risks
Key risks include execution on manufacturing scale-up for power lipo, potential delays in surgeon adoption, and continued tariff impacts on input costs. The company’s cash position is adequate through 2028, but higher-than-expected cash burn or slower margin improvement could pressure future liquidity. OEM revenue attrition is expected, and any missteps in the core aesthetics segment could leave the business exposed.
Forward Outlook
For Q3 2026, APYX expects continued momentum in surgical aesthetics, with power lipo handpiece shipments ramping and handpiece utilization increasing.
- Full-year 2026 revenue guidance reaffirmed at $59 million to $60 million.
- Surgical aesthetics segment expected at $54 million to $55 million; OEM at $5 million.
- Gross margin guided to 62% to 63%, with operating expenses capped at $45 million.
Management highlighted confidence in AON uptake, ongoing cost discipline, and the expectation of improving handpiece manufacturing efficiency in the second half.
- Power lipo rollout is embedded in current guidance, with upside possible from additional tariff relief not yet included.
- Recurring revenue growth from handpieces and consumables is expected to be the primary driver of margin improvement.
Takeaways
Investors should focus on the pace of AON adoption, handpiece utilization trends, and the company’s ability to scale manufacturing while managing cash burn.
- Platform-Driven Growth: AON’s all-in-one approach and clinical validation are winning new accounts and expanding procedure volumes, anchoring APYX’s growth thesis.
- Margin and Cash Flow Trajectory: Near-term gross margin pressure from manufacturing scale-up is expected to ease, but cash flow breakeven will depend on both volume ramp and disciplined expense management.
- Future Watchpoints: Monitor for acceleration in recurring handpiece sales, further clinical data releases, and any updates on tariff relief or OEM wind-down pacing.
Conclusion
APYX is executing a focused transition from legacy OEM to a high-margin, recurring revenue model anchored by its AON platform. The next phase hinges on scaling manufacturing, deepening surgeon adoption, and capturing the expanding body contouring opportunity fueled by demographic shifts and GLP-1 therapies.
Industry Read-Through
The APYX quarter underscores a broader industry pivot toward integrated technology platforms and procedural ecosystems in aesthetics. GLP-1 driven weight loss is reshaping the patient pool for body contouring, creating new demand for surgical solutions that address both fat removal and skin laxity. Competitors in the aesthetics and medtech space should expect heightened focus on clinical validation, recurring revenue models, and platform stickiness as key differentiators. Margin volatility tied to manufacturing scale and tariffs is likely to persist for smaller device makers, while those able to build a consumables-driven model will be best positioned for sustainable growth.